Omid Farokhzad Sells 8,068 Shares of Seer, Inc. (NASDAQ:SEER) Stock

Seer, Inc. (NASDAQ:SEER) CEO Omid Farokhzad sold 8,068 shares of the business’s stock in a transaction on Tuesday, February 4th. The stock was sold at an average price of $2.24, for a total value of $18,072.32. Following the completion of the transaction, the chief executive officer now directly owns 1,428,217 shares of the company’s stock, valued at approximately $3,199,206.08. This trade represents a 0.56 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website.

Seer Price Performance

Shares of NASDAQ SEER remained flat at $2.28 during midday trading on Wednesday. 73,514 shares of the stock were exchanged, compared to its average volume of 154,831. The stock has a market capitalization of $134.45 million, a P/E ratio of -1.75 and a beta of 1.58. Seer, Inc. has a 1-year low of $1.51 and a 1-year high of $2.63. The stock’s 50-day simple moving average is $2.37 and its 200 day simple moving average is $2.07.

Institutional Investors Weigh In On Seer

Hedge funds have recently made changes to their positions in the business. AQR Capital Management LLC acquired a new position in Seer during the second quarter worth approximately $30,000. Y Intercept Hong Kong Ltd purchased a new position in shares of Seer in the fourth quarter valued at $36,000. Quadrature Capital Ltd boosted its position in Seer by 301.7% in the 3rd quarter. Quadrature Capital Ltd now owns 57,088 shares of the company’s stock valued at $112,000 after buying an additional 42,875 shares during the last quarter. XTX Topco Ltd acquired a new stake in Seer during the 3rd quarter valued at approximately $123,000. Finally, Barclays PLC raised its holdings in Seer by 34.1% in the third quarter. Barclays PLC now owns 64,426 shares of the company’s stock valued at $127,000 after acquiring an additional 16,382 shares in the last quarter. Institutional investors and hedge funds own 75.20% of the company’s stock.

About Seer

Seer, Inc, a life sciences company, engages in developing and commercializing products to decode the biology of the proteome. It develops Proteograph Product Suite, an integrated solution that includes proprietary engineered nanoparticles, consumables, automation instrumentation, and software to perform proteomic analysis to provide a solution that can be incorporated by nearly any lab for research use only.